{
    "title": "109_hr3696",
    "content": "The \"Medical Advertising Reform Act\" is the short title of this Act. It focuses on labeling and advertising for prescription drugs, specifically addressing advertising regulations for prescription drugs. The \"Medical Advertising Reform Act\" focuses on advertising regulations for prescription drugs. It amends the Federal Food, Drug, and Cosmetic Act to require prior approval by the Secretary for consumer advertisements of prescription drugs. Non-consumer advertisements may not require prior approval except in extraordinary circumstances. The Federal Food, Drug, and Cosmetic Act is amended to require approval for consumer advertisements of prescription drugs. The Secretary can extend the two-year advertising restriction period if necessary for public health protection. Enforcement includes penalties for failure to comply with advertising requirements. The amendments made to the Federal Food, Drug, and Cosmetic Act require approval for consumer advertisements of prescription drugs and include penalties for failure to comply with advertising requirements. The amendments do not affect the Secretary of Health and Human Services' authority under the Public Health Service Act. The Secretary of Health and Human Services must submit a report to Congress proposing the inclusion of information on comparative effectiveness and cost-effectiveness of prescription drugs in their labeling and advertisements. This report should also outline necessary amendments to the Federal Food, Drug, and Cosmetic Act. Funding of $25,000,000 authorized for Division of Drug Marketing, Advertising, and Communications for fiscal year 2007, with additional funding for subsequent years. Title II focuses on advertising for restricted medical devices. Section 502(r) of the Federal Food, Drug, and Cosmetic Act is amended to require prior approval by the Secretary for consumer advertisements of restricted devices. Approval or denial must be issued within 30 days. Regulations for non-consumer advertisements may not require prior approval except in extraordinary circumstances. The Comptroller General of the United States will conduct a study on the impact of consumer-directed advertising on restricted device utilization and spending from January 1, 2001, through December 31, 2005. This study will analyze the growth in retail sales and annual price increases of the 25 most heavily advertised devices compared to others. The Comptroller General will evaluate the impact of advertising on national healthcare consumption and spending, including regulatory controls for consumer-directed device advertising. The Comptroller General will assess the effectiveness of regulatory controls for consumer-directed device advertising and recommend remediation if deficiencies are found. Definitions for \"device\" and \"restricted device\" are provided for clarity. The Comptroller General will submit a report to Congress by July 1, 2006, detailing findings and recommendations from a study on regulatory controls for consumer-directed device advertising. SEC. 202. Funding of $5,000,000 authorized for Office of Compliance within the Center for Devices and Radiological Health for fiscal years 2007-2009, with additional funding as needed for subsequent years. The Secretary of Health and Human Services will provide objective health information to the public through a toll-free number, public awareness campaigns, and the website www.healthfinder.gov. Authorization of appropriations is provided for public information campaigns. Authorized appropriations for public information campaigns for fiscal years 2007 through 2009."
}